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There is a requirement for an eﬃcacious vaccine to protect people against infection from Francisella tularensis, the etiological agent
of tularemia. The lipopolysaccharide (LPS) of F. tularensis is suboptimally protective against a parenteral lethal challenge in mice.
To develop a more eﬃcacious subunit vaccine, we have used a novel biosynthetic technique of protein glycan coupling technology
(PGCT) that exploits bacterial N-linked glycosylation to recombinantly conjugate F. tularensis O-antigen glycans to the
immunogenic carrier protein Pseudomonas aeruginosa exoprotein A (ExoA). Previously, we demonstrated that an ExoA
glycoconjugate with two glycosylation sequons was capable of providing signiﬁcant protection to mice against a challenge with a
low-virulence strain of F. tularensis. Here, we have generated a more heavily glycosylated conjugate vaccine and evaluated its
eﬃcacy in a Fischer 344 rat model of tularemia. We demonstrate that this glycoconjugate vaccine protected rats against disease
and the lethality of an inhalational challenge with F. tularensis Schu S4. Our data highlights the potential of this biosynthetic
approach for the creation of next-generation tularemia subunit vaccines.
1. Introduction
Tularemia is caused by the intracellular bacterium Francisella
tularensis. This bacterium can cause a range of presentations
of disease in humans. In the most severe cases where infec-
tion is acquired by the pulmonary route, the mortality rate
was found to be between 30 and 60% prior to the introduc-
tion of antibiotics [1]. The more virulent F. tularensis subsp.
tularensis strains are endemic across North America. Lower
virulence strains, including F. tularensis subsp. holarctica
are endemic more widely in the Northern Hemisphere across
Europe, America, and Asia. These high- and low-virulence
strains are commonly designated as type A and type B
strains, respectively [2]. Extrapolation of data from human
aerosol infection studies has estimated that lung deposition
of a single colony forming unit (CFU) may be suﬃcient to
establish infection [3]. The bacterium is categorised by the
US Centers for Disease Control and Prevention as a Tier 1
biological select agent due to its low infectious dose via the
aerosol route and disease severity. Development of a safe
and eﬀective vaccine to protect against aerosol challenge with
this bacterium remains a priority.
F. tularensis subsp. holarctica live vaccine strain (LVS)
has been previously used in humans to protect against tulare-
mia in at-risk populations such as laboratory workers. This
vaccine was tested in humans experimentally and shown to
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protect against disease resulting from aerosol challenges of
up to 20,000CFU [4, 5]. Whilst demonstrating good eﬃcacy,
the mechanisms of its attenuation remain poorly deﬁned.
Phase II clinical trials to determine the safety and immunoge-
nicity of LVS remain ongoing [6]. To provide a more deﬁned
alternative to LVS, several engineered live attenuated
vaccines have been constructed which have demonstrated
eﬃcacy in animal models of disease [7–12]. In comparison
with live attenuated candidates, safety compliance require-
ments for potential licensure are expected to be easier to
achieve with subunit vaccines. However, overcoming eﬃcacy
limitations of subunit candidates has been the challenge to
date. The only protein subunit candidate that has provided
partial protection against type A strains of F. tularensis is
IglC, but that was when delivery was through the use of
a live attenuated Listeria monocytogenes vector [13]. Cur-
rently, lipopolysaccharide (LPS) is the only deﬁned subunit
F. tularensis vaccine antigen that has been reported to pro-
vide protection to immunised animals, although principally
only against the lower virulence strains [14–17]. Therefore,
whilst LPS remains a promising subunit candidate, strategies
to improve its eﬃcacy are warranted.
As LPS is a T cell-independent antigen, a strategy
employed to enhance protective immunity for vaccines
developed and licensed for other human pathogens is the
incorporation of an antigenic carrier protein to the polysac-
charide subunit. This approach has been successfully
employed for several licensed public health vaccines includ-
ing against Neisseria meningitidis, Haemophilus inﬂuenzae
type B, and Streptococcus pneumoniae [18]. As proof of con-
cept for the beneﬁts of this approach in the ﬁeld of tularemia,
conjugation of F. tularensis LPS to bovine serum albumin
induced protective immunity against type B, but not type
A, strains of F. tularensis in mice [17].
These traditional conjugation approaches require the
puriﬁcation of the glycan from the native bacteria and then
chemical conjugation of the glycans to a suitable carrier pro-
tein. This multistep approach can be time consuming, costly,
and susceptible to variations between bioconjugation prepa-
ration batches. An alternative protein conjugation strategy
adopted by our laboratory is the use of protein glycan
coupling technology (PGCT) which facilitates the in vitro
transfer of glycans to a recombinant acceptor protein using
the glycosylating enzyme PglB from Campylobacter jejuni
[19–22]. The presence of the PglB gene locus allows coupling
of glucans to recombinantly expressed proteins containing
the acceptor sequon D/E-X-N-Y-S/T, where X and Y are
any amino acid except proline. We previously utilised PGCT
to transfer recombinantly synthesized F. tularensis subsp.
tularensis O-antigen to the carrier protein Pseudomonas
aeruginosa exoprotein A (ExoA). This glycoconjugate was
engineered to contain two glycosylation sequons and was
produced using an Escherichia coli expression system [23].
We demonstrated that this glycoconjugate signiﬁcantly
improved the protection from disease in mice infected with
F. tularensis subsp. holarctica compared to immunisation
with LPS alone [23].
In the current study, we have introduced a further
eight sequons into the sequence of ExoA resulting in a
protein conjugate more highly glycosylated with F. tularensis
O-antigen sugars. To allow stringent eﬃcacy evaluation of
this next-generation vaccine, we have developed a Fischer
344 (F344) rat inhalational challenge model and demon-
strated that this subunit glycoconjugate vaccine can protect
rats against an aerosol challenge of the high-virulence strain
of F. tularensis Schu S4.
2. Materials and Methods
2.1. Francisella Bacterial Strains and Culture. For vaccination
of rats with LVS, a lyophilised vial of LVS (National Drug
Biologic Research Company, USA, lot number 4) was recon-
stituted in phosphate-buﬀered saline (PBS, Life Technologies,
UK), inoculated onto blood cysteine glucose agar (BCGA),
and incubated at 37°C for 48 h. Bacterial growthwas recovered
from the agar and resuspended in PBS, and the optical density
at 600nm (OD600) was adjusted to 0.14. The suspension
was serially diluted ten-fold to the desired concentration
for immunisation.
For challenge studies, F. tularensis Schu S4 was inocu-
lated onto BCGA and incubated at 37°C for 24h. Growth
was recovered from agar, resuspended in PBS, and the
OD600 adjusted to 0.1. One mL of this suspension was
inoculated into 100mL of modiﬁed cysteine partial hydro-
lysate (MCPH) broth with 4% glucose and incubated with
shaking at 180 rpm, at 37°C for 48 h. OD600 of the culture
was adjusted to 0.1 in PBS and serially diluted to the
desired concentration for aerosol challenge. Challenge
inoculum quantiﬁcation was determined by plating serially
diluted cultures onto BCGA and incubating at 37°C for
48–72h.
To determine bacterial load in organs, organs were
weighed, homogenised through a 40μm cell sieve, serially
diluted in PBS, plated onto BCGA, and incubated at 37°C
for 48–72h.
2.2. Production of the Glycoconjugate Vaccine (GtExoA)
2.2.1. Bacterial Strains and Plasmid Construction. Escherichia
coli CLM24 [24] was used as the host strain for protein
expression and glycoconjugate production. CLM24 (a ligase
negative strain) was stably transformed with the plasmid
pGab2 [23], a construct created from the insertion of the
F. tularensis subspecies tularensis strain Schu S4 O-antigen
coding region into the low copy number expression plasmid
pLAFR [25]. pGab2 is tetracycline selectable and consti-
tutively expressed. Following conﬁrmation of the expres-
sion of the F. tularensis O-antigen, the resulting strain
was then transformed with the plasmid CLM24 contain-
ing a plasmid-encoded C. jejuni pglB, pGVXN114, which
expresses the C. jejuni oligosaccharyltransferase PglB.
Finally, the resulting strain was transformed with the plasmid
pGVXN150: GtExoA, creating a three plasmid system for the
production of the glycoconjugate. The GtExoA construct was
engineered to express a modiﬁed version of P. aeruginosa
exotoxin A that was synthesized by Celtek Bioscience LLC,
USA in the vector pGH and closed into a vector derived
from pEC415 using the restriction enzymes NheI and
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EcoRI (NEB, UK). The synthesized protein contains two
internal modiﬁcations that allow glycosylation of the protein
by PglB [23], as well as containing four N-glycosylation
sequons at the N terminus and an additional 4 at the C
terminus. In addition, a hexahistidine tag was added to
the C terminus of the protein to facilitate puriﬁcation and
an E. coli DsbA signal peptide was added to the N-terminal
sequences enabling Sec-dependent secretion to the peri-
plasm. pGVXN150: GtExoA is ampicillin resistant and
L-(+)-arabinose inducible. The construct sequence was then
conﬁrmed using Sanger sequencing with the primers GtExoA
NF (GCGCTGGCTGGTTTAGTTT), GtExoA NR (CGCA
TTCGTTCCAGAGGT), GtExoA CF (GACAAGGAACA
GGCGATCAG), and GtExoA CR (TGGTGATGATGGTG
ATGGTC).
2.2.2. Culture and GtExoA Glycoprotein Expression
Conditions. For all experiments, E. coli CLM24 was cultured
in Luria-Bertani (LB) broth (Fisher Scientiﬁc, UK) supple-
mented with appropriate antibiotics in the following concen-
trations: ampicillin 100μg/mL, tetracycline 20μg/mL, and
spectinomycin 80μg/mL. The addition of manganese chlo-
ride at the time of protein and PglB induction was at a ﬁnal
concentration of 4mM, and made up as a 1M stock fresh
prior to each experiment. Cultures were incubated at 37°C
shaking at 110 rpm for 16–20hrs for large-scale prepara-
tion. For three-plasmid system glycoconjugate production,
an overnight LB culture of E. coli CLM24 harbouring
pGVXN114, pGVXN150: GtExoA, and pGab2 were subcul-
tured in a 1 : 10 dilution of LB broth (Fisher Scientiﬁc) with
antibiotics, and grown to mid log phase. pGVXN150:
GtExoA was induced by the addition of 0.2% L-(+)-arabinose
(Sigma-Aldrich, UK), and C. jejuni PglB was induced with
1mM IPTG, followed by incubation for an initial 4 hours.
Another addition of 0.4% L-(+)-arabinose was then added
and cultures were incubated overnight.
2.2.3. Production and Puriﬁcation of Glycoconjugate Vaccine.
1.8 L of LB was inoculated with a 200mL starter culture and
grown to an OD590 of 0.60–0.80, then induced as described
above. The next day, induced glycoconjugate pellets were
harvested via centrifugation at 5300×g at 4°C for 30 minutes
and were resuspended in ice-cold lysis buﬀer (50mM
NaH2PO4, 300mM NaCl, and 10mM imidazole) containing
1mg/mL lysozyme (Sigma-Aldrich) and 0.15μL Benzonase®
Nuclease (Novagen®, UK). Lysis, wash, and elution buﬀer
were all adjusted to pH8 with 5M NaOH. Resuspended cells
were subjected to ﬁve rounds of lysis using a prechilled
Stansted High Pressure Cell Disruptor (Stansted Fluid Power
Ltd., UK) under 60,000 psi (410MPa) in continuous mode.
Cell debris was subsequently pelleted by spinning at
7840×g at 4°C for 60 minutes. The resulting supernatant
was kept on ice whilst being loaded onto a GE Healthcare,
UK, HIS-trap HP 1mL column. Then, the column was
washed in buﬀer containing 50.0mM NaH2PO4, 300mM
NaCl, and 20mM imidazole whilst attached to an AKTA
puriﬁer. Material was eluted and collected in 1mL fractions
with an imidazole gradient of 30–500mM elution buﬀer that
also contained 20% v/v glycerol and 5% w/v glucose. The
collected fractions were visualised by Western blot, and the
glycosylated GtExoA fractions were pooled and concentrated
using buﬀer exchange columns (Vivaspin 2 (Vivaproducts,
UK)) into PBS 20% v/v glycerol, prior to quantiﬁcation with
a BCA Protein Assay Kit (Pierce Biotechnology, USA).
2.2.4. Western Blot Analysis. To assess protein expression and
glycosylation levels, a two-channel simultaneous Western
blot (Odyssey LI-COR, LI-COR Biosciences, Hamburg
Germany) was used to analyse AKTA puriﬁed elution frac-
tions. Freshly eluted samples were resuspended in 2x Laemmli
buﬀer and boiled at 95°C for 6 minutes. Boilates, and a
PageRuler Plus Prestained Protein Ladder (Life Technologies)
were separated on a NuPAGE 10% Bis-Tris Gel Novex®, then
transferred to a Hybond™-C Extra nitrocellulose membrane
(Amersham Biosciences, UK). The membrane was then
blocked in 2% w/v skim milk and PBS 0.2% v/v Tween 20
(Sigma-Aldrich) overnight at 4°C. The next day, membranes
were probed simultaneously with two primary antibodies:
O-antigen presence was detected using the mouse monoclo-
nal antibody FB-11 (1 : 10,000) (Abcam, UK) and GtExoA
was detected with rabbit anti-HIS polyclonal antibodies
(1 : 5000) (Abcam). Secondary antibodies were Goat anti-
Rabbit IRDye® 680RD and Goat anti-Mouse IRDye®
800CW (Odyssey® LI-COR Biosciences, UK) both diluted
1 : 10,000.
2.3. Animal Procedures
2.3.1. Ethics Statement. Animals were kept in accordance
with the UK Animals (Scientiﬁc Procedures) Act 1986 and
Codes of Practice for the Housing and Care of Animals used
in Scientiﬁc Procedures 1989. The license application under-
went approval by the local ethical review process with the
Defence Science and Technology Laboratory (Dstl) Animal
Welfare and Ethical Review Body (AWERB) before submis-
sion and approval with the UK Home Oﬃce and Animal
Procedures Committee (an independent committee that
oﬀers advice to The Secretary of State of the ethics of the
proposed work). The project license that covered this work
was 30/3166. No prespeciﬁed eﬀect size was predicted for
the glycoconjugate, and therefore no sample size estimate
was made. No randomisation of animals or blinding of inves-
tigators was used in this study. No animals were excluded
from the study.
2.3.2. Animals. Female F344 rats were obtained from Envigo,
UK. Rats were implanted with BioThermo microchips
(Identipet, SA) by subcutaneous (s.c.) injection to allow indi-
vidual rats to be tracked and have their temperaturemeasured
through the study. Rats used in vaccine studies were 12–16
weeks of age and weighed 190±20 g at the start of the proce-
dures. On arrival in the conventional animal unit and on
transfer of rats into containment level 3 animal facilities, rats
were acclimatised to their new surroundings for 10 days
before any procedures were performed. Rats were housed in
cages ofﬁve, in polypropylene cages with a stainless steelmesh
cover with an integral water bottle holder and diet hopper
which conformed to the Code of Practice for the housing of
animals bred, supplied, or used for scientiﬁc purposes
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(December 2014). Rats were kept under a 12 hour light/dark
cycle (350 to 400 Lux during the day, 10 Lux during the night,
with a ramp up and ramp down period at “dawn” and “dusk”)
at 19 to 23°Cand 45 to 65% relative humidity. Cages contained
8/10 and 10/14 grade corn cob (International Product
Supplies, UK) as a nesting material with a range of environ-
mental enrichment added throughout the studies (e.g., irradi-
ated aspen wood, Des.Res. rat houses (LBS, UK)), and there
was free access to food (Labdiet certiﬁed rodent diet 5002
and Labdiet EU rodent 22% diet 5LF5; International Product
Supplies) and water throughout the study. During immunisa-
tion and the subsequent rest period, rats were housed in a con-
ventional animal unit, in rooms supplied with rough ﬁltered
air giving 20 to 25 air changes per hour. For challenge with
F. tularensis Schu S4, all animals were handled under UK
Advisory Committee on Dangerous Pathogens animal con-
tainment level 3 conditions within a half-suit isolator compli-
ant with British Standard BS5726, supplied with an inward
ﬂow of HEPA-ﬁltered air giving 35 to 45 air changes per hour.
The room was supplied with double HEPA-ﬁltered air giving
20 to 25 air changes per hour.
2.3.3. Experimental Animal Procedures. Rats were vaccinated
with LVS in PBS via the s.c. route. Rats were vaccinated with
10μg GtExoA coadministered with the MF59 adjuvant
(Novartis, UK) in a 100μL volume via the s.c. or intraperito-
neal (i.p.) route 3 times, 2 weeks apart. Control groups of rats
(n = 5) were also immunised by the i.p. and s.c. routes
with the MF59 adjuvant alone or with PBS by the s.c. route.
Aerosol challenge with F. tularensis Schu S4 occurred ﬁve
weeks following ﬁnal vaccination. Following challenge,
animals were observed twice daily and signs of disease and
subcutaneous temperature were recorded. Disease signs were
assigned a score. The presence of piloerection and eye prob-
lems were scored given a clinical score of 1 or 2 depending
on severity. Hunched posture, rapid breathing, and pinched
posture were each given a clinical score of 1 if present.
If any additional abnormal clinical signs were observed
(e.g., pale tail), they were assigned a score of 1. A cumulative
score for disease at each observed timepoint was calculated.
Animals were weighed once daily. A humane endpoint was
applied to rats in a moribund state or where their tempera-
ture was less than 33°C. Animals underwent euthanasia with
intraperitoneally administered sodium pentobarbitone.
2.3.4. Aerosol Challenge. Rats were exposed to an aerosol of
F. tularensis Schu S4 by the inhalational route in a nose-
only exposure unit (EMMS, UK) utilising a 6-jet Collison
atomiser (Dstl, in-house) attached to a contained Henderson
Piccolo arrangement to condition the aerosol to 50% (±5%)
relative humidity. The nose-only exposure unit was con-
trolled by the Aerosol Management Platform (AeroMP)
aerosol system (Biaera Technologies L.L.C., USA). The ani-
mals were exposed to the aerosolised bacteria for 10 minutes,
with impingement of the aerosol cloud sampled at the mid-
way point of challenge into PBS via an All-Glass Impinger
(AGI-30; Ace Glass, Vineland, NJ, USA). Following the
challenge, the impinged aerosol was enumerated by serial
dilution, plated onto BCGA plates, and incubated at 37°C
for 48 h. The challenge dose was calculated from the aerosol
concentration (CFU/L of air) using Guyton’s formula [26]
for minute respiratory volume and assuming 40% retention
of 1–3μm droplets [27].
2.4. Immunological Assays
2.4.1. Cell Isolation and Culture. Rat spleens were homoge-
nised through a 40μm sieve using a sterile syringe plunger
and collected into L15 medium (Life Technologies). The iso-
lated splenocytes were diluted to 2× 106 cells/mL in medium
and cultured in the presence of either medium alone, soni-
cated LVS whole cells (10μg/mL, Dstl), sonicated Schu S4
whole cells (10μg/mL, Dstl), puriﬁed ExoA (5μg/mL,
London School of Hygiene and Tropical Medicine, UK), or
Concanavalin-A (Con-A, 5μg/mL, Sigma-Aldrich). For cul-
tures of cells from LVS-infected or PBS control rats, spleno-
cytes were diluted in L15 medium supplemented with 10%
foetal bovine serum (Sigma-Aldrich), nonessential amino
acids (Life Technologies), 2-mercaptoethanol (Life Technol-
ogies), 100U/mL penicillin, and 100mg/mL streptomycin
sulphate (Life Technologies) and then cultured at 37°C in
the absence of a controlled CO2 environment. For cultures
of cells from vaccinated rats, splenocytes were diluted in
RPMI 1640 medium (Life Technologies), supplemented as
described above, and then cultured at 37°C with 5% CO2.
2.4.2. Measurement of IFNγ by Enzyme-Linked Immunosorbent
Assay (ELISA). Splenocytes (2×105 per assay well) were cul-
tured in duplicate in the presence of the antigen for 72 hours
(see above), and supernatants were harvested and stored
at −20°C prior to use. The expression of IFNγ was determined
in plasma supernatants using a commercial rat IFNγ ELISA
kit (Mabtech, Sweden) with responses determined by the
measurement of optical density at 450nm (OD450nm).
2.4.3. ELISA for Anti-GtExoA Antibody Titre. Plates were
coated with 5μg/mL GtExoA in PBS, 100μL per well, and
incubated at 4°C overnight. After blocking with 1% skimmed
milk powder in PBS for 2 hours at 37°C, plates were washed
three times with 0.05% Tween 20 (Sigma-Aldrich) in PBS.
Sera from individual rats were applied to plates at 1 : 50 and
serially diluted 1 : 2 across the plate, in 1% skimmed milk
powder. Bound IgG rat antibody was detected using anti-
rat antibody conjugated to HRP at 1 : 2000 in PBS and
developed using 10mM 2,2′-azino-bis(3-ethylbenzothiazo-
line-6-sulphonic acid) in citrate buﬀer with 0.01% H2O2.
OD was measured at 450nm. Antibody titre was deﬁned as
the reciprocal of the highest dilution of serum that had a
mean OD value at least 3 standard deviations higher than
the mean OD of nonvaccinated serum.
2.5. Statistical Analysis. Analysis of rat weight data was per-
formed using IBM SPSS version 21.0. All other statistical
analyses were performed using GraphPad Prism version
6.02. The statistical tests applied to the diﬀerent data sets
are described in the corresponding ﬁgure legends.
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3. Results
3.1. Production of the GtExoA Glycoconjugate Vaccine. The
glycoconjugate vaccine previously evaluated by our group
was glycosylated via two sequons incorporated into the ExoA
carrier protein [23]. To improve the ratio of glycan to protein
in the conjugate, a further 8 sequons were introduced into
ExoA resulting in a more highly glycosylated conjugate,
GtExoA. Recognition of GtExoA by a monoclonal antibody,
FB-11, with speciﬁcity towards F. tularensis O-antigen
demonstrated conservation of sugar moieties (Figure 1). No
binding of FB-11 was observed in ExoA lacking the glycosyl-
ation sequons (Figure 1, lane 1). Western blot analysis of
puriﬁed glycoconjugate vaccines demonstrated an increase
in the molecular size of the decaglycosylated GtExoA com-
pared with the biglycosylated ﬁrst generation conjugate
(Figure 1). This observation was commensurate with an
expected increase in glycosylation resulting from the inclu-
sion of the additional sequons. Due to the increased antigenic
potential of this glycoconjugate vaccine, GtExoA was priori-
tised for eﬃcacy evaluation.
3.2. Development of a F344 Rat Rodent Model of Inhalational
Tularemia to Allow Eﬃcacy Evaluation of Candidate
Vaccines. F344 rats have recently gained popularity as a
preferred rodent model for assessing tularemia vaccines. In
comparison with mice, F344 rats are considered to provide
a closer approximation of human disease [28, 29] and demon-
strate a more comparable response to LVS vaccination [30].
We therefore ﬁrst developed an in-house F344model of inha-
lational tularemia to allow stringent evaluation of GtExoA.
Groups of 5 rats were challenged with a range of doses
of F. tularensis Schu S4 via the aerosol route to determine
an appropriate infectious dose. The estimated inhaled dose
ranged from approximately 10CFU to 3.15× 104CFU. All
rats challenged with 2.94× 102 to 3.15× 104CFU succumbed
to infection within 14 days of challenge (Figure 2(a)). Of rats
challenged with approximately 10CFU, only 1 animal out of
5 survived to the end of the experiment at 21 days postinfec-
tion. During the recovery of this animal, its disease signs
resolved and some weight was recovered. The mean lethal
dose (MLD) was therefore estimated to be less than 10CFU
via the aerosol route in our model.
Bacterial dissemination was determined at day 7 post-
challenge in groups of up to ﬁve sacriﬁced rats. Animals
sacriﬁced at this time had highly colonised lungs, liver, and
spleens (Supplementary Figure S1). All infected rats showed
severe signs of disease. Rats initially exhibited piloerection
and developed eye problems, including secretion of
porphyrin and ptosis of the eyelids until their eyes were
completely closed, followed by a hunched posture alongside
rapid breathing. Rats became more lethargic and less
responsive to stimuli over the course of disease (Figure 2(b)).
All infected rats lost weight in a dose-dependent manner
(Figure 2(c)) and displayed a febrile stage, with subcutaneous
temperatures which were raised at least 1.5°C above their
baseline temperature (Figure 2(d)). Rats which received the
highest challenge of 3.15× 104CFU rapidly lost between 7
and 10 percent of their body weight within 5 days of
challenge. Those rats which received a lower challenge all
lost at least 10 percent of their starting weight, and in some
cases more than 25 percent of body weight, but over a
greater length of time. These data were used to identify
disease parameters useful for assessing candidate vaccine
performance in the model.
3.3. GtExoA Glycoconjugate Vaccine Induces Memory
Immunity in Vaccinated F344 Rats. To determine whether
the GtExoA glycoconjugate vaccine could induce memory
immunity in rats prior to proceeding to a biosafety level 3
eﬃcacy challenge study, groups of 5 rats were vaccinated with
GtExoA in combination with the MF59 adjuvant. Groups
were vaccinated by i.p. or s.c. administration routes. We
previously used the i.p. vaccination route to assess the ﬁrst
generation glycoconjugate vaccine in mice [13], whilst s.c. is
the immunisation route routinely used for LVS, the tularemia
gold-standard reference vaccine. Therefore, both immunisa-
tion routes were assessed to allow translation between mouse
and rat models and to control for the s.c. immunisation route
used for LVS administration. Rats were vaccinated on 3
occasions, 2 weeks apart. Control groups included PBS
sham-vaccinated rats, MF59 adjuvant-only-immunised rats
and a group vaccinated with LVS. Serum and splenocytes
were recovered 28 days after the ﬁnal vaccination to measure
IgG- and cell-mediated responses, respectively. Sera from
the MF59 adjuvant-only-vaccinated controls showed no
130
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70
kDa M 1 2
(a) (b) (c)
3 M 1 2 3 M 1 2 3
Figure 1: Recombinant ExoA modiﬁed to incorporate additional glycosylation sequons is heavily glycosylated by F. tularensis O-antigen by
C. jejuni PglB in E. coli CLM24. Samples were separated by SDS-PAGE, and then two-colour Western blots were used to simultaneously
detect the degree of glycosylation of ExoA using (a) a monoclonal mouse antibody (FB-11) with speciﬁcity to F. tularensis O-antigen (red)
and (b) rabbit polyclonal antibodies with speciﬁcity to the 6x His sequence (green). The two IR secondary antibody channels when
overlaid (IR 800/680) result in images with overall yellow colour indicating conjugation (c). M, protein ladder marker; lane 1, pGVXN150
only; lane 2, pGVXN150 ExoA glycosylated with the F. tularensis O-antigen (same construct from Cuccui et al. [23]); and lane 3, GtExoA
heavily glycosylated with the F. tularensis O-antigen due to the presence of an additional eight glycosylation sequons.
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appreciable binding to the GtExoA antigen, whilst endpoint
IgG titres from rats vaccinated with GtExoA by the i.p. or
s.c. routes were 1 : 204800 and 1 : 102400, respectively
(Figure 3(a)). Antigen-stimulated expression of IFNγ was
used as a measure of T cell-mediated memory. Signiﬁcantly
elevated ExoA-stimulated IFNγ responses were only
observed in rats immunised with GtExoA (Figure 3(b)) con-
ﬁrming the recognition of the ExoA conjugate protein by the
cell-mediated compartment of these rats. No increase in
ExoA-stimulated IFNγ from splenocytes isolated from rats
immunised with the MF59 adjuvant by i.p. or s.c. routes
was observed (data not shown). Stimulation of splenocytes
with the crude F. tularensis antigen preparations only
resulted in signiﬁcantly elevated IFNγ expression in the
group of rats vaccinated with LVS (Figure 3(b)). Elevated
IFNγ responses stimulated by F. tularensis Schu S4 sonicate
in the GtExoA-vaccinated groups of rats, potentially as a
consequence of nonspeciﬁc stimulation by components in
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Figure 2: Survival and disease progression of rats following an aerosol challenge with a range of doses of F. tularensis Schu S4. (a) F344 rats
(n = 5) were challenged via the aerosol route with a range of F. tularensis Schu S4 doses (see accompanying legend). Rats were monitored daily
for mortality, and data were reported on the Kaplan-Meier survival curve. Calculated retained dose for each challenge group is shown on the
Kaplan-Meier survival curve. (b) Clinical signs of disease were monitored twice daily. Average cumulative signs for each group are presented
for animals which had not succumbed to disease. (c) Weight was monitored daily. Average weight change for each group is presented for
animals which had not succumbed to disease. (d) Temperature was monitored twice daily. Average animal temperature for each group is
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this crude antigen extract, were not signiﬁcantly stronger than
responses observed in PBS-immunised rats (Figure 3(b)) or
control rats immunised with MF59 alone (data not shown).
3.4. GtExoA Glycoconjugate Protects against Pulmonary
Tularemia in F344 Rats. To evaluate the eﬃcacy of our glyco-
conjugate vaccine, groups of 5 rats were vaccinated with the
GtExoA by both the s.c. and i.p. routes along with appropri-
ate MF59 adjuvant controls. A group of rats (n = 5) was also
vaccinated with 5× 107CFU LVS via the s.c. route. The LVS
group was included to validate the relevance of the model,
whilst also providing a reference gold standard against which
to assess the performance of our GtExoA vaccine candidate.
Five weeks after the ﬁnal vaccination, rats were challenged
with an aerosol of 5.48× 102F. tularensis Schu S4 (the calcu-
lated retained dose). All LVS- and GtExoA bioconjugate-
vaccinated rats survived 21 days postaerosol challenge
(Figure 4(a)). One of the ﬁve rats vaccinated with the MF59
adjuvant alone via the s.c. route survived to 21 days postin-
fection but the group survival curve was still signiﬁcantly dif-
ferent from rats vaccinated via the s.c. route with GtExoA
(p < 0 05) (Figure 4(a)). Similarly, despite one of the ﬁve
PBS-immunised rats surviving 21 days postinfection, survival
was signiﬁcantly diﬀerent from rats vaccinated via the s.c.
route with LVS (Figure 4(a), p < 0 05). However, as a con-
sequence of three of the ﬁve rats vaccinated with MF59
alone via the i.p. route not succumbing to a lethal infection,
the diﬀerence between their survival and that of the com-
parable i.p. GtExoA vaccine group did not reach signiﬁ-
cance (p = 0 168, log-rank test). The level of signiﬁcance
for the comparison of all survival curves is presented in
Supplementary Table S1.
Rats vaccinated with GtExoA by either route, or with
LVS, showed no clinical signs of disease (Figure 4(b)) and
did not become febrile (Supplementary Figure S2). In
contrast, rats vaccinated with PBS subcutaneously and MF59
only via i.p. and s.c. routes all became febrile with maximal
febrile temperature being observed on day 5 postinfection.
On day 5, the temperature of rats in the groups vaccinated
with LVS or GtExoA (i.p. and s.c. routes) were all
signiﬁcantly lower than those in the PBS control group
(p < 0 001, 0.001, and 0.01, respectively, ANOVA with
Dunnett’s postanalysis test), see Figure 4(c). There was no
signiﬁcant diﬀerence between the temperature of the PBS
or MF59 (i.p. and s.c. routes) adjuvant control rats.
Furthermore, all PBS- and MF59-only-immunised rats
showed clinical signs of disease including those that did not
ultimately succumb to a lethal infection (Figure 4(b)).
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Figure 3: GtExoA glycoconjugate stimulates memory immunity in vaccinated rats. Groups of F344 rats (n = 5) were vaccinated three times,
two weeks apart with 10μg of GtExoA coadministered with MF59, or immunised with MF59 alone, and immune responses were measured 28
days after the third immunisation. (a) Quantitation of rat IgG recognising the GtExoA glycoconjugate antigen was determined by ELISA for a
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expression of IFNγ in 72-hour culture supernatants was measured by ELISA. The OD450nm results were normalised by transformation
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determined by one-way ANOVA with Holm-Sidak’s posttests (∗∗p < 0 01, ∗∗∗p < 0 001, or ∗∗∗∗p < 0 0001). Data validity was tested using
Bartlett’s test for equal variance. IFNγ responses are presented as mean response for each group (n = 5) ±SEM.
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Figure 4: GtExoA protects F344 rats against aerosol infection with F. tularensis Schu S4. Groups of F344 rats (n = 5) were vaccinated three
times, two weeks apart with 10μg GtExoA coadministered with MF59, or immunised with MF59 alone, via the s.c. or i.p. route, or 5.38× 107
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all groups with equivalent power.
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Weight change in rats after challenge was shown to be
signiﬁcantly diﬀerent over time between all groups of vacci-
nated rats and their relevant controls (Figure 4(d)). Weight
change in rats vaccinated with LVS or with GtExoA via the
i.p. route signiﬁcantly diverged from their relevant controls
on day 4 (Figures 4(d.1) and 4(d.3), p < 0 005, p < 0 0005,
respectively). Weight change between rats vaccinated with
GtExoA by the s.c. route and the relevant control rats sig-
niﬁcantly diverged on day 2 after challenge (Figure 4(d.2),
p < 0 05). The control rats that did not reach a humane
endpoint all resolved signs of disease and had recovered
some weight by 21 days following infection. F. tularensis
was not detected in the lungs, liver, or spleen of LVS- or
GtExoA-vaccinated rats at 21 days postinfection whilst
all surviving MF59- or PBS-only-vaccinated rats were
colonised with F. tularensis in the lung, liver, and spleen
at 21 days postinfection.
4. Discussion
The development of a subunit vaccine that can protect against
inhalational infection with type A strains of F. tularensis
remains an important goal for tularemia vaccine research.
To this end, we have utilised PGCT to recombinantly express
the immunogenic P. aeruginosa carrier protein ExoA glyco-
sylated with O-antigen sugars of F. tularensis in a single-step
process. We previously used this approach to engineer a gly-
conjugate incorporating two sequons and demonstrated the
protective potential of this biglycosylated vaccine in a murine
model of tularemia [23]. Here, we have engineered a second
generation vaccine by introducing a further 8 sequons into
the conjugate protein ExoA to increase the antigen potential
of the glycoconjugate. The glycans were recognised by a
monoclonal antibody with speciﬁcity for the terminal moiety
4,6-dideoxy-4-formamido-D-glucose of the F. tularensis
subsp. tularensis and subsp. holarctica O-antigen [31]. The
recognition by this antibody conﬁrmed the presence of struc-
turally conserved sugars. Furthermore, increasing the number
of sequons in the second generation conjugate successfully
resulted in a more heavily glycosylated conjugate, as con-
ﬁrmed by its increased molecular size. Together, these data
demonstrate the versatility of this technology for generating
glycoconjugate vaccine candidates. It is currently unclear
how many repeating units are transferred by C. jejuni PglB
in this system. The native F. tularensis O-antigen consists of
a repeating tetrasaccharide structure [14]. The absence of a
ladder of multiple-sized products separated by SDS-PAGE
suggests that GtExoA principally carries single repeat units
at its sequon sites. Eﬀorts to modulate the level of C. jejuni
PglB to increase the chain length of repeat glycan units is
ongoing in the Wren laboratory.
Recent development of a F344 rat model of respiratory
tularemia for testing vaccine candidates has provided the
opportunity for testing candidates in a closer approximation
of human disease [28, 29]. Tularemia in rats is less acute than
in mice, reﬂecting human disease progression more closely.
In addition, F344 rats show similar sensitivity to F. tularensis
strains as humans [32] and rats can be protected from disease
by vaccination with LVS [30]. We consider that establishing
an aerosol-initiated rat model of tularemia at our centre,
commensurate with that developed by Hutt et al. [29], to be
an important step in allowing eﬃcacy evaluation of both
GtExoA and future subunit tularemia vaccines. In our aero-
sol challenge model, lethal infection could be established with
less than 10CFU of F. tularensis Schu S4. This conﬁrms the
disease susceptibility of F344 rats to inhalation of type A
strains of F. tularensis reported previously [28, 29, 33]. LVS
has been shown to protect F344 rats against respiratory infec-
tion by F. tularensis Schu S4 delivered by the aerosol route
[34] and more recently by the intratracheal route [28]. The
inclusion of LVS as a comparative reference vaccine in our
eﬃcacy study conﬁrms that this is also the case following
infection by the aerosol delivery methodology employed in
our study. These data mimic protection invoked by LVS
against F. tularensis delivered by the aerosol route in humans
reported during human experiments in the 1960s [5, 35],
supporting the value of this model for eﬃcacy evaluation of
tularemia vaccine candidates.
Analysis of the GtExoA Kaplan-Meier survival curves
indicated that a signiﬁcant survival beneﬁt was observed for
the s.c. but not i.p. immunisation route when compared with
the corresponding MF59 adjuvant control rats. This was due
to survival of 3/5 rats that received the MF59 adjuvant by the
i.p. route. Although we allowed a 5-week interval between the
ﬁnal vaccination and challenge with F. tularensis, we would
hypothesise that i.p. immunisation with MFP59 results in a
prolonged stimulation of innate immunity. However, it
should be noted that none of the GtExoA-vaccinated rats,
regardless of immunisation route, showed clinical signs of
disease or demonstrated weight loss. In contrast, all of the
control rats, including all those that did not succumb to the
lethal infection, showed weight loss and adverse clinical
signs. Therefore, even where signiﬁcant protection against
lethality was not observed, complete protection against
clinical disease was. Given that pneumonic infections by
high-virulence strains of F. tularensis exhibited <60%mortal-
ity in humans in the preantibiotic era [1], we would advocate
the beneﬁts of the rat model in being able to measure protec-
tion against lethal and nonlethal disease outcomes. The
inclusion of the i.p. immunisation route in this study was
primarily to provide consistency with the route used in
our previous mouse eﬃcacy study [19]. We would not envis-
age this as an appropriate immunisation route for future
clinical extrapolation.
The protection provided by GtExoA delivered by the s.c.
route was comparable to LVS in this study. This is a signiﬁ-
cant achievement for a tularemia subunit vaccine in view of
the use of an aerosol challenge model using a type A strain
of F. tularensis. Whilst undoubtedly promising, it would be
premature to state the vaccine to be as protective as LVS.
Since the data presented is derived from a single eﬃcacy
study, it provides proof of concept of eﬃcacy in this prelim-
inary study. The challenge dose employed in this study was
approximately 500CFU. LVS has demonstrated that it can
protect F344 rats against lethal challenges approaching
105CFU of F. tularensis Schu S4 delivered by the i.t. route
[28]. Therefore, it will be important to test the eﬃcacy of
GtExoA in future dose escalation challenge studies to fully
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establish its protective potential compared with the eﬃcacy
bench mark set by LVS.
Since the O-antigen of F. tularensis is a T cell-
independent antigen, we would hypothesise that the protec-
tion observed was principally mediated by the generation
of protective antibody responses. We detected strong titres
of glycoconjugate-speciﬁc IgG in serum from GtExoA-
vaccinated rats. Whilst O-antigen is widely acknowledged
as a serodominant antigen, we did not formally quantitate
the relative contribution of the O-antigen and ExoA protein-
speciﬁc IgG. In mice, we previously demonstrated that the
conjugation of the O-antigen glycans to the carrier protein
ExoA resulted in enhanced antibody concentrations com-
pared with using LPS alone [13]. This was believed to be
due to ExoA providing T cell help to promote more eﬃcient
antibody generation. In the current study, we conﬁrmed that
vaccination of rats with GtExoA also resulted in the genera-
tion of ExoA-speciﬁc cell-mediated immunity supporting
this hypothesis. Understanding the immunological basis
and duration of the protective immunity generated by our
glycoconjugate vaccine will be an important consideration
for future studies.
The next step toward the development of glycoconjugate
vaccines produced by this PGCT technology would be to
incorporate F. tularensis peptide antigens as the O-antigen
carrier protein, rather than P. aeruginosa ExoA. This
approach has been successfully applied to a PGCT-produced
Staphylococcus aureus glycoconjugate vaccine. Switching the
carrier protein from ExoA to the S. aureus-speciﬁc protein
Hla resulted in improved vaccine eﬃcacy [36]. Whilst no
single peptide antigen has been shown to be protective as a
vaccine candidate for F. tularensis type A strains in mice,
several recombinant F. tularensis proteins have been shown
to invoke a cellular immune response [37–39]. Moreover,
encapsulated recombinant peptide antigens [40], and recently
amultiantigenTobaccoMosaic virus-based vaccine [41], have
been shown to protect against lethal LVS challenge to mice.
An F. tularensis antigen expressed as part of a whole cell
vaccine platformhas also been shown to boost eﬃcacy of a live
attenuated vaccine [13]. It is therefore considered that incor-
poration of immunogenic F. tularensis antigens into a glyco-
conjugate vaccine is a desirable next step in the development
of this candidate. A combination of the humoral response to
the O-antigen, boosted by T cell help due to conjugation to
protein, alongside the cellular response to F. tularensis-
speciﬁc T cell epitopes has the potential to improve the
protection demonstrated by the existing candidate. Future
optimisation of dosing schedules and choice of adjuvant
will also be important development considerations.
5. Conclusions
Wehave utilised PGCT technology to produce an F. tularensis
O-antigen ExoA glycoconjugate vaccine. We have developed
a F344 rat aerosol challenge model which has been used to
generate proof of concept data demonstrating that this
O-antigen glycoconjugate vaccine can protect against an
aerosol challenge of F. tularensis Schu S4. Testing of the
next generation of glycoconjugate vaccine candidates in
this rat model of aerosol-delivered F. tularensis should
allow delineation of the eﬃcacies of this new source of
candidates and would be the next strategic step towards
development of a protective and licensable human vaccine
to protect against tularemia.
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